Bid Banana
PricingBid helpAPILog inStart free trial
Log inStart free trial

Before you respond

  • Federal grantsHow to Find Grants for Nonprofits
  • Healthcare RFPsHealthcare and Medical Services Bids and Bidding Guide
  • How to apply for a grantGrant Applications vs. RFPs: Writing Differences Explained
More healthcare and medical services bids →Must-win bid? Bring in The Bid Lab →
Bid Banana
SearchPricingBid helpBrowse bidsAPISupportFAQPrivacy PolicyTerms of UseAI Use Policy

This website and its content is copyright of The Bid Lab © 2026. The Bid Lab is a trademark of Bid Lab, LLC. All rights reserved.

  1. Bid Banana
  2. ›Bids
  3. ›Federal
  4. ›Integrating Biospecimen Science Approaches into Clinical…

U.S. National Institutes of Health·United States of America

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)

Closes 9/10/2027$200k – $1MGrants Notice
Get bids like this by emailBid source

Description

This opportunity aims to support extramural research that investigates and mitigates challenges in clinical assay development due to preanalytical variability in biospecimens. The research will focus on understanding how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers. The goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices. Key aspects of this opportunity include: • Investigating preanalytical variability associated with biospecimen procurement and study • Exploring how different biospecimen preanalytical conditions affect biomarkers • Improving understanding of how analytical quantification of biomarkers is affected by biospecimen collection, processing, and storage procedures • Supporting research that can lead to evidence-based standardization of biopsy handling practices

Attached files

Contact

National Institutes of Health(NIH Grants Information)

[email protected]

(301) 402-2541

Key dates

Opened
12/13/2024
Closes
9/10/2027

Last updated

Details

Type
Grants Notice
Industry
Healthcare and Medical Services
NAICS
541710
Solicitation №
PAR-25-325

Budget estimate

$200,000 – $1,000,000

The potential budget for this grant is difficult to estimate without more specific information on the funding available. However, considering the National Institutes of Health's budget and typical grant sizes, a reasonable estimate might be between $200,000 and $1,000,000. This range is based on the assumption that the grant will support a research project with a moderate to large scope, involving multiple researchers and institutions. Factors that may influence the likely payment range include the number of awards, the duration of the project, and the specific requirements of the research.

AI estimate from the solicitation

Similar opportunities

Matched by Bid Banana AI™

Bid Banana · 1.6M+ bids and awards 🍌

You found this one. Bid Banana has 1.6M+ bids and awards.

You found this bid by looking. Bid Banana searches open government bids across all 50 states, updated daily, so you stop hunting: save a search once and we email you your new matches, daily or weekly.

1.6M+
bids & awards
All 50
states
4,000+
agencies
Start your 7-day free trial

Plans from $49.99/month. Cancel anytime, no setup fees.

Built by The Bid Lab, answering RFPs since 2017.

U.S. National Institutes of Health·United States of America

Top match · 81%

Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)

Closes 3/1/2027Opened 1/8/2026

U.S. National Institutes of Health·United States of America

78% match

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Closes 10/8/2027Opened 11/21/2024

U.S. National Institutes of Health·United States of America

78% match

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

Closes 2/7/2027Opened 12/8/2025

U.S. National Institutes of Health·United States of America

77% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

76% match

Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)

Closes 3/5/2029Opened 7/22/2025

U.S. National Institutes of Health·United States of America

76% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. National Institutes of Health·United States of America

76% match

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

Closes 1/7/2028Opened 10/28/2024

U.S. National Institutes of Health·United States of America

76% match

NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)

Closes 7/5/2029Opened 7/8/2025

U.S. National Institutes of Health·United States of America

75% match

Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed)

Closes 2/15/2028Opened 9/16/2026

U.S. National Institutes of Health·United States of America

75% match

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Closes 2/11/2027Opened 1/13/2026

U.S. National Institutes of Health·United States of America

75% match

Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)

Closes 9/7/2027Opened 3/8/2022

U.S. National Institutes of Health·United States of America

74% match

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Closes 11/10/2026Opened 9/8/2025

U.S. National Institutes of Health·United States of America

74% match

BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)

Closes 2/8/2027Opened 6/16/2023

U.S. National Institutes of Health·United States of America

74% match

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

Closes 11/5/2027Opened 11/15/2021

U.S. National Institutes of Health·United States of America

74% match

NIH Brain Development Cohorts (NBDC) and�Population Assessment of Tobacco and Health (PATH) Study�Biospecimen Access (X01 Clinical Trial Not Allowed)

Closes 4/17/2029Opened 9/10/2025

U.S. National Institutes of Health·United States of America

73% match

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

Closes 5/25/2029Opened 6/16/2025

U.S. National Institutes of Health·United States of America

73% match

Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)

Closes 10/9/2028Opened 4/9/2026

U.S. National Institutes of Health·United States of America

73% match

Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)

Closes 4/15/2027Opened 10/29/2024

U.S. National Institutes of Health·United States of America

73% match

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Closes 6/3/2027Opened 7/14/2026

U.S. Food and Drug Administration·United States of America

73% match

Novel approaches to support therapeutic development in ultra-rare cancers

Rolling / TBD closeOpened 8/4/2025

U.S. National Institutes of Health·United States of America

73% match

Somatic Mosaicism across Human Tissues (SMaHT) Program: Experimental and Computational Technology Development (RM1 Clinical Trial Not Allowed)

Closes 6/30/2027Opened 9/14/2026

U.S. Food and Drug Administration·United States of America

73% match

Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed

Rolling / TBD closeOpened 11/24/2023

U.S. National Institutes of Health·United States of America

73% match

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Closes 11/5/2029Opened 2/11/2026

U.S. National Institutes of Health·United States of America

73% match

Investigator Initiated Innovation in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)

Closes 9/7/2027Opened 11/18/2024

U.S. Food and Drug Administration·United States of America

73% match

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

Rolling / TBD closeOpened 11/24/2023